F

Fulcrum Therapeutics
D

FULC

8.64000
USD
-0.12
(-1.37%)
مغلق
حجم التداول
16,281
الربح لكل سهم
-1
العائد الربحي
-
P/E
-8
حجم السوق
467,583,304
أصول ذات صلة الأخبار المقالات

العنوان: Fulcrum Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.